GYRE Stock Analysis: Buy, Sell, or Hold?
GYRE - Gyre Therapeutics, Inc. Common Stock
$6.13
0.00 (0.00%)
▲
5d:
+4.61%
30d:
-0.81%
90d:
-12.93%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When GYRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GYRE shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: GYRE shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: GYRE is currently trading at $6.13, which is considered fair relative to its 30-day fair value range of $5.82 to $6.26. From a valuation perspective, the stock is trading at a discount (Forward PE: -53.3) compared to its historical average (45.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GYRE is in a strong downtrend. Immediate support is located at $5.74, while resistance sits at $6.35.
Market Sentiment: GYRE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.67 (+204.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GYRE is in a strong downtrend. Immediate support is located at $5.74, while resistance sits at $6.35.
Market Sentiment: GYRE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.67 (+204.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$5.82 -
$6.26
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
88.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 204.5% below Wall St target ($18.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$5.82 -
$6.26
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$5.74
Resistance Level
$6.35
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-53.30
Wall Street Target
$18.67
(+204.5%)
Revenue Growth (YoY)
2.1%
Earnings Growth (YoY)
166.2%
Profit Margin
-5.4%
PE vs Historical
-53.3 vs 45.4
CHEAP
Share & Embed Analysis
Last updated: June 23, 2026 6:28 PM ET
Data refreshes hourly during market hours. Next update: 7:28 PM
Data refreshes hourly during market hours. Next update: 7:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GYRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
|
MNMD
Mind Medicine Inc |
STRONG BUY
11 analysts |
$29 | 62 BUY |
|
ALLO
Allogene Therapeutics Inc |
STRONG BUY
14 analysts |
$8 | 60 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 59 HOLD |
